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Cancer is one of  the leading 
causes of  death among Americans. It is 
estimated that approximately one-third 
of  all Americans will be diagnosed with 
some form of  cancer in the next 20 years 
(World Health Organization [WHO]). 
There are numerous types of  cancer but 
the most common types are lung cancer, 
breast cancer (women) and prostate 
cancer (men), which also happens to 
have the highest mortality rate (WHO). 
Because these three forms of  cancer are 
very dangerous, it is important to learn 
more about cancer to find a cure. 
Unlike normal cells, cancer cells have 
the enzyme telomerase which prevents 
telomeres from degenerating so that 
the cell continues to divide (El-Daly et 
al., 2005). One of  the drugs often used 
to treat cancer patients are telomerase 
inhibitors, but cancer cells are becoming 
increasingly resistant to the drug. BIBR 
1532 is a known telomerase inhibitor 
and is currently in clinical trials for 
treating cancers. For a drug to be a good 
telomerase inhibitor like BIBR 1532, it 
must have a carboxylic acid structure 
bonded to an aromatic ring and a 
conjugated amine.
 There were 18 drugs synthesized 
in the Department of  Chemistry in 
the labs of  Dr. Robert Smart and Dr. 
William Schroeder based on the structure 
of  BIBR 1532. These drugs have been 
tested in our lab to see whether they 
show any antiproliferative effect. Out of  
the 18 drugs screened, about 4-5 drugs 
(4-43A, WS 1248, WS 76, WS 648, WS 
1214) have shown an antiproliferative 
effect when tested against metastatic 
prostate cell lines that have known high 
telomerase activity. The drugs identified 
with anti-telomerase activity will be tested 
first at different concentrations to find 
the optimal concentration that inhibits 
proliferative activity. After the optimal 
concentration is identified, all the cells 
will be treated at this concentration 
and the treated cells will be frozen until 
further use for telomerase assay. Those 
drugs with antiproliferative effects will 
be further tested to see if  they are good 
telomerase inhibitors by subjecting them 
to telomerase assays. The cell will be 
lysed and analyzed using TRAP assay 
to test whether the telomerase present in 
the cancer cell is inhibited by the drug or 
through a different mechanism. 
This research is important because 
if  the drugs tested are proven to be good 
telomerase inhibitors then they could be 
used to effectively treat prostate, breast 
and lung cancer, which are known to have 
high telomerase activity and are known to 
be fatal.
